Biology and natural history of prostate cancer and the role of chemoprevention

International Journal of Clinical Practice

Volumn 64, Issue 13, 2010, Pages 1746-1753

  Rosenberg, M T ^a   Froehner, M ^b   Albala, D ^c   Miner, M M ^d  

^a Mid Michigan Health Centers Jackson   (United States)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c CROUSE HOSPITAL   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; CARCINOGEN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GLEASON SCORE; GYNECOMASTIA; HEART FAILURE; HORMONE SYNTHESIS; HUMAN; KIDNEY DISEASE; LIBIDO DISORDER; MALE; MALE SEXUAL DYSFUNCTION; METASTASIS; MOLECULAR MECHANICS; PATIENT EDUCATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT CANCER; REVIEW; RISK REDUCTION; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE METABOLISM; TISSUE GROWTH;

5-ALPHA REDUCTASE INHIBITORS; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PRECANCEROUS CONDITIONS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECURRENCE; TESTOSTERONE;

EID: 78649256753     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02541.x     Document Type: Review

References (65)

1. American Cancer Society. (accessed September 2010).
2. Rittmaster RS,. 5α-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 2008; 22: 389 - 402.
3. Scardino PT,. The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc 2000; 111: 201 - 41.
4. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977 - 83.
5. Klotz L,. Active surveillance for prostate cancer: a review. Curr Urol Rep 2010; 11: 165 - 71.
6. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242 - 8.
7. Epstein JI,. An update of the Gleason grading system. J Urol 2010; 183: 433 - 40.
8. Lu-Yao GL, Albertson PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302: 1202 - 9.
9. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB,. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: S6 - 11.
10. Tindall DJ, Rittmaster RS,. The rationale for inhibiting 5α-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008; 179: 1235 - 42.
11. De Marzo AM, Meeker AK, Zha S, et al. Human prostate cancer precursors and pathobiology. Urology 2003; 62: 55 - 62.
12. Brawer MK,. Prostatic intraepithelial neoplasia: an overview. Rev Urol 2005; 7 (suppl 3): S11 - 8.
13. Steiner MS,. High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction. World J Urol 2003; 21: 15 - 20.
14. Chrisofos M, Papatsoris AG, Lazaris A, Deliveliotis C,. Precursor lesions of prostate cancer. Crit Rev Clin Lab Sci 2007; 44: 243 - 70.
15. Zhu YS, Sun GH,. 5α-reductase isozymes in the prostate. J Med Sci 2005; 25: 1 - 12.
16. Marks LS,. 5α-reductase: history and clinical importance. Rev Urol 2004; 6 (suppl 9): S11 - 21.
17. Pereira de Jésus-Tran K, Côté PL, Cantin L, Blanchet J, Labrie F, Breton R,. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci 2006; 15: 987 - 99.
18. Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM,. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 2007; 282: 25801 - 16.
19. Wright AS, Thomas LN, Douglas RC, Lazier CB, Rittmaster RS,. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 1996; 98: 2558 - 63.
20. Morley JE, Kaiser FE, Perry HM III, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410 - 3.
21. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR,. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724 - 31.
22. Gray A, Feldman HA, McKinlay JB, Longcope C,. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016 - 25.
23. Pirke KM, Doerr P,. Age related changes in free plasma testosterone, dihydrotestosterone and oestradiol. Acta Endocrinol (Copenh) 1975; 80: 171 - 8.
24. Morgentaler A, Traish AM,. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310 - 21.
25. Morgentaler A, Rhoden EL,. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/ml or less. Urology 2006; 68: 1263 - 7.
26. Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA,. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008; 72: 1240 - 5.
27. Sofikerim M, Eskicorapci S, Oruc O, Ozen H,. Hormonal predictors of prostate cancer. Urol Int 2007; 79: 13 - 8.
28. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE,. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213 - 5.
29. Imperato-McGinley J, Zhu YS,. Androgens and male physiology the syndrome of 5α-reductase-2 deficiency. Mol Cell Endocrinol 2002; 198: 51 - 9.
30. Andersson S, Russell DW,. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci U S A 1990; 87: 3640 - 4.
31. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW,. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 1992; 89: 293 - 300.
32. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW,. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 1993; 92: 903 - 10.
33. Bonkhoff H, Stein U, Aumüller G, Remberger K,. Differential expression of 5α-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996; 29: 261 - 7.
34. Iehlé C, Radvanyi F, Gil Diez de MS, et al. Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999; 68: 89 - 195.
35. Pelletier G, Luu-The V, Huang XF, Lapointe H, Labrie F,. Localization by in situ hybridization of steroid 5α-reductase isozyme gene expression in the human prostate and preputial skin. J Urol 1998; 160: 577 - 82.
36. Singh RP, Agarwal R,. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006; 13: 751 - 78.
37. Debes JD, Tindall DJ,. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 2002; 187: 1 - 7.
38. Burnstein KL,. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 2005; 95: 657 - 69.
39. Sarvis JA, Thompson IM,. Androgens and prevention of prostate cancer. Curr Opin Endocrinol Diabetes Obes 2008; 15: 271 - 7.
40. Balk SP, Knudsen KE,. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008; 6: e001.
41. Roddam AW, Allen NE, Appleby P, Key TJ,. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170 - 83.
42. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006; 91: 3850 - 6.
43. Mohler JL, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440 - 8.
44. Thomas LN, Douglas RC, Vessey JP, et al. 5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 2003; 170: 2019 - 25.
45. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005; 63: 231 - 9.
46. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ,. Type 1 and type 2 5α-reductase expression in the development and progression of prostate cancer. Eur Urol 2008; 53: 244 - 52.
47. Thomas LN, Douglas RC, Lazier CB, et al. Levels of 5α-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008; 179: 147 - 51.
48. Uemura M, Tamura K, Chung S, et al. Novel 5 α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008; 99: 81 - 6.
49. Andriole G, Bostwick D, Civantos F, et al. The effects of 5α-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol 2005; 174: 2098 - 104.
50. Frye SV,. Discovery and clinical development of dutasteride, a potent dual 5α-reductase inhibitor. Curr Top Med Chem 2006; 6: 405 - 21.
51. Proscar® (Finasteride) Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc, 2007.
52. Avodart® (Dutasteride) Prescribing Information. Research Park Triangle, NC: GlaxoSmithKline, 2010.
53. Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990; 70: 1136 - 41.
54. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215 - 24.
55. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185 - 91.
56. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128 - 33.
57. Thompson IM, Tangen CM, Goodman PJ, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007; 177: 1749 - 52.
58. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 1375 - 83.
59. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 2004; 172: 1314 - 7.
60. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192 - 202.
61. Deutsche Gesellschaft für Urologie e. V.: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der Verschiedenen Stadien des Prostatakarzinoms. Version 1.01 - Oktober 2009. Verfügbar auf der Website des Ärztlichen Zentrums für Qualität in der Medizin (ÄZQ): (accessed September 2010).
62. American Urological Association: Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update (Reviewed and Validity Confirmed 2009.). (accessed September 2010).
63. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Update 2010.) (accessed September 2010).
64. National Institute for Health and Clinical Excellence (NICE): NICE Clinical Guideline 58: Prostate Cancer. Diagnosis and treatment. (accessed September 2010).
65. Kramer BS, Hagerty KL, Justman S, et al. Use of 5α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncolgy/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009; 181: 1642 - 57.